External validity of trials on amyloid‐lowering therapy against Alzheimer’s disease: the population‐based Rotterdam Study

Jacqueline Josephine Claus, Ilse vom Hofe, Annekee van Ijzinga Veenstra, Silvan Licher, Harro Seelaar, Frank Jan De Jong, Julia Neitzel, Meike W Vernooij, Arfan Ikram, Frank J Wolters · 2025

Read External validity of trials on amyloid‐lowering therapy against Alzheimer’s disease: the population‐based Rotterdam Study by Jacqueline Josephine Claus, Ilse vom Hofe, Annekee van Ijzinga Veenstra, Silvan Licher, Harro Seelaar, Frank Jan De Jong, Julia Neitzel, Meike W Vernooij, Arfan Ikram, Frank J Wolters (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712050.txt.

Description

Jacqueline Josephine Claus and co-authors ask how many real patients would even qualify for the new Alzheimer's antibody trials. The drugs slow decline in early disease, but trial gates are tight. Their 2025 study takes the gate rules for three antibodies and applies them to a population cohort in Rotterdam. The cohort held 968 older adults with mild memory loss or early dementia, all fully assessed.

About four in ten failed the first gate: no amyloid in the brain. Past that, three-quarters or more tripped a health-based rule for two of the drugs. Heart disease and blood thinner use blocked the most people. The third drug barred fewer, near three in five. The team warns that trial wins may reach a narrow slice of clinic patients.

Catalog record

CREATORJacqueline Josephine Claus, Ilse vom Hofe, Annekee van Ijzinga Veenstra, Silvan Licher, Harro Seelaar, Frank Jan De Jong, Julia Neitzel, Meike W Vernooij, Arfan Ikram, Frank J Wolters
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712050

Browse the full library · About the Tower of Babel